Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment.
In the era of Helicobacter pylori, our concepts about peptic ulcer disease have undergone a major paradigm shift. New ways of thinking about the etiology of ulcers are leading to new treatment modalities. Treating peptic ulcers with antibiotics is an idea that would have been laughed at a mere decade ago, yet it has become the standard of care for H. pylori-associated disease. Our current state of knowledge, and where we seem to be heading, is the subject of this review.
Cohen
J C
JC
Department of Medicine, State University of New York Health Science Center at Syracuse, USA.
D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D012307:Risk Factors
D000863:Antacids; D000900:Anti-Bacterial Agents